

Neil J Stone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5711181/publications.pdf>

Version: 2024-02-01

222
papers

40,175
citations

36303

51
h-index

2895

190
g-index

229
all docs

229
docs citations

229
times ranked

33677
citing authors

#	ARTICLE	IF	CITATIONS
1	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Circulation</i> , 2004, 110, 227-239.	1.6	5,602
2	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Circulation</i> , 2014, 129, S1-45.	1.6	4,842
3	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2889-2934.	2.8	3,414
4	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2935-2959.	2.8	3,277
5	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. <i>Circulation</i> , 2014, 129, S49-73.	1.6	2,823
6	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
7	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. <i>Circulation</i> , 2002, 106, 388-391.	1.6	1,623
8	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	2.8	1,550
9	Triglycerides and Cardiovascular Disease. <i>Circulation</i> , 2011, 123, 2292-2333.	1.6	1,511
10	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Journal of the American College of Cardiology</i> , 2004, 44, 720-732.	2.8	1,207
11	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3168-3209.	2.8	1,128
12	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2017, 136, e1-e23.	1.6	884
13	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 114-126.	1.6	634
14	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. <i>Circulation</i> , 2007, 115, 1481-1501.	1.6	600
15	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Diabetes Care</i> , 2007, 30, 162-172.	8.6	577
16	Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia. <i>Circulation</i> , 1974, 49, 476-488.	1.6	444
17	Dietary Guidelines for Healthy American Adults. <i>Circulation</i> , 1996, 94, 1795-1800.	1.6	376
18	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1046-e1081.	1.6	361

#	ARTICLE	IF	CITATIONS
19	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1230-1250.	2.8	359
20	Limitations of the Electrocardiographic Response to Exercise in Predicting Coronary-Artery Disease. <i>New England Journal of Medicine</i> , 1975, 293, 367-371.	27.0	309
21	Atorvastatin Inhibits Hypercholesterolemia-Induced Cellular Proliferation and Bone Matrix Production in the Rabbit Aortic Valve. <i>Circulation</i> , 2002, 105, 2660-2665.	1.6	296
22	Recent National Cholesterol Education Program Adult Treatment Panel III Update: Adjustments and Options. <i>American Journal of Cardiology</i> , 2005, 96, 53-59.	1.6	208
23	Metabolic Studies in Familial Hypercholesterolemia. <i>Journal of Clinical Investigation</i> , 1979, 64, 524-533.	8.2	200
24	Managing Abnormal Blood Lipids. <i>Circulation</i> , 2005, 112, 3184-3209.	1.6	199
25	American Heart Association Guide for Improving Cardiovascular Health at the Community Level. <i>Circulation</i> , 2003, 107, 645-651.	1.6	197
26	Antiatherosclerotic and Antithrombotic Effects of Omega-3 Fatty Acids. <i>American Journal of Cardiology</i> , 2006, 98, 39-49.	1.6	168
27	Genetics of the LDL receptor: Evidence that the mutations affecting binding and internalization are allelic. <i>Cell</i> , 1977, 12, 629-641.	28.9	164
28	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. <i>Annals of Internal Medicine</i> , 2014, 160, 339-343.	3.9	164
29	Secondary causes of hyperlipidemia. <i>Medical Clinics of North America</i> , 1994, 78, 117-141.	2.5	155
30	AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2008, 102, 1631-1643.	1.6	148
31	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. <i>Journal of the American College of Cardiology</i> , 2021, 78, 960-993.	2.8	146
32	Clinician-Patient Risk Discussion for Atherosclerotic Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1361-1368.	2.8	142
33	Fish Consumption, Fish Oil, Lipids, and Coronary Heart Disease. <i>Circulation</i> , 1996, 94, 2337-2340.	1.6	139
34	Lifestyle Modification for Metabolic Syndrome: A Systematic Review. <i>American Journal of Medicine</i> , 2014, 127, 1242.e1-1242.e10.	1.5	131
35	Coronary Heart Disease Risks Associated with High Levels of HDL Cholesterol. <i>Journal of the American Heart Association</i> , 2014, 3, e000519.	3.7	99
36	The Telehealth Ten: A Guide for a Patient-Assisted Virtual Physical Examination. <i>American Journal of Medicine</i> , 2021, 134, 48-51.	1.5	90

#	ARTICLE	IF	CITATIONS
37	Shared Decision-Making and Patient Empowerment in Preventive Cardiology. <i>Current Cardiology Reports</i> , 2016, 18, 49.	2.9	89
38	A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients. <i>American Journal of Cardiology</i> , 2015, 115, 1760-1766.	1.6	80
39	A Clinician's Guide to Healthy Eating for Cardiovascular Disease Prevention. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 251-267.	2.4	72
40	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	2.8	72
41	Treatment of metabolic syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 213-228.	1.5	67
42	Approach to Treatment of the Patient with Metabolic Syndrome: Lifestyle Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 15-21.	1.6	67
43	ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3). <i>Journal of the American College of Cardiology</i> , 2015, 65, 1721-1723.	2.8	67
44	Putative atherogenic factors in patients with chronic renal failure. <i>Progress in Cardiovascular Diseases</i> , 1983, 26, 133-144.	3.1	64
45	Fasting or Nonfasting Lipid Measurements. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1227-1234.	2.8	63
46	Rapid Diet Assessment Screening Tools for Cardiovascular Disease Risk Reduction Across Healthcare Settings: A Scientific Statement From the American Heart Association. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e000094.	2.2	60
47	Secondary Prevention for Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1121-1123.	1.6	56
48	A Summary of Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1329-1330.	2.4	55
49	Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?. <i>Stroke</i> , 2007, 38, 441-450.	2.0	55
50	Clinical Status and Cardiovascular Risk Profile of Adults with a History of Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2011, 159, 795-801.	1.8	55
51	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. <i>European Heart Journal</i> , 2015, 36, 2110-2118.	2.2	55
52	Statins, risk assessment, and the new American prevention guidelines. <i>Lancet</i> , 2014, 383, 600-602.	13.7	50
53	Statins for Primary Prevention in Older Adults—Moving Toward Evidence-Based Decision Making. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2188-2196.	2.6	50
54	Lipid management: Current diet and drug treatment options. <i>American Journal of Medicine</i> , 1996, 101, 40S-49S.	1.5	49

#	ARTICLE	IF	CITATIONS
55	Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents. <i>Journal of Pediatrics</i> , 1998, 133, 242-246.	1.8	48
56	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. <i>World Journal of Cardiology</i> , 2016, 8, 201.	1.5	47
57	National heart, lung, and blood institute type II coronary intervention study: Design, methods, and baseline characteristics. <i>Contemporary Clinical Trials</i> , 1982, 3, 91-111.	1.9	45
58	Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept. <i>American Journal of Cardiology</i> , 2006, 98, 1405-1408.	1.6	43
59	Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥ 190 mg/dL. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004652.	2.2	43
60	Statin use and lower extremity amputation risk in nonelderly diabetic patients. <i>Journal of Vascular Surgery</i> , 2013, 58, 1578-1585.e1.	1.1	42
61	Relation of Body Mass Index to Late Survival After Valvular Heart Surgery. <i>American Journal of Cardiology</i> , 2012, 110, 1667-1678.	1.6	39
62	Reliability of assessing change with sequential coronary angiography. <i>American Heart Journal</i> , 1982, 104, 816-823.	2.7	38
63	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol—Secondary Prevention. <i>JAMA Cardiology</i> , 2019, 4, 589.	6.1	38
64	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*. <i>Annals of Internal Medicine</i> , 2019, 170, 779.	3.9	38
65	Perspective: Childhood Obesity Requires New Strategies for Prevention. <i>Advances in Nutrition</i> , 2020, 11, 1071-1078.	6.4	38
66	The Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto miocardio (GISSI)-Prevenzione trial on fish oil and vitamin E supplementation in myocardial infarction survivors. <i>Current Cardiology Reports</i> , 2000, 2, 445-451.	2.9	33
67	2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. <i>JAMA Cardiology</i> , 2019, 4, 488.	6.1	33
68	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 375-383.	3.1	32
69	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. <i>Diabetes Care</i> , 2020, 43, 1673-1678.	8.6	31
70	Statins in Very Elderly Adults (Debate). <i>Journal of the American Geriatrics Society</i> , 2014, 62, 943-945.	2.6	30
71	Familial hypercholesterolemia: a challenge of diagnosis and therapy.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 57-64.	1.3	29
72	The clinical and economic significance of atherosclerosis. <i>American Journal of Medicine</i> , 1996, 101, 6S-9S.	1.5	28

#	ARTICLE	IF	CITATIONS
73	What to say and how to say it. <i>Current Opinion in Cardiology</i> , 2016, 31, 537-544.	1.8	28
74	How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. <i>European Heart Journal</i> , 2021, 42, 2154-2169.	2.2	28
75	Hyperlipoproteinemia and coronary heart disease. <i>Progress in Cardiovascular Diseases</i> , 1972, 14, 341-359.	3.1	25
76	Obesity Paradox in Amputation Risk Among Nonelderly Diabetic Men. <i>Obesity</i> , 2012, 20, 460-462.	3.0	25
77	Focus on lifestyle change and the metabolic syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 493-508.	3.2	24
78	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention. <i>Journal of the American Heart Association</i> , 2014, 3, e001098.	3.7	24
79	Patients and Physicians Beliefs and Practices Regarding Adherence to Cardiovascular Medication. <i>JAMA Cardiology</i> , 2016, 1, 470.	6.1	24
80	Metabolic Syndrome: An Evolving Clinical Construct. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 172-177.	3.1	24
81	Relation of Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement. <i>American Journal of Cardiology</i> , 2017, 119, 1832-1838.	1.6	24
82	Therapeutic lifestyle change and adult treatment panel III: Evidence then and now. <i>Current Atherosclerosis Reports</i> , 2002, 4, 433-443.	4.8	23
83	Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 140, 1018-1027.	0.8	23
84	Addressing Statin Adverse Effects in the Clinic. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 533-542.	2.0	22
85	Statin Use and Aneurysm Risk in Patients With Bicuspid Aortic Valve Disease. <i>Clinical Cardiology</i> , 2016, 39, 41-47.	1.8	22
86	The ASCVD Risk Estimator App. <i>Journal of the American College of Cardiology</i> , 2016, 67, 350-352.	2.8	22
87	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , 2016, 62, 428-435.	3.2	22
88	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018ÂAHA/ACC Cholesterol Guidelines. <i>Journal of the American College of Cardiology</i> , 2019, 74, 712-714.	2.8	21
89	EFFECTS OF DIETARY MODIFICATION AND TREATMENT OF OBESITY. <i>Medical Clinics of North America</i> , 2000, 84, 95-122.	2.5	20
90	Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke. <i>American Journal of Cardiology</i> , 2007, 99, S1-S35.	1.6	20

#	ARTICLE	IF	CITATIONS
91	Emphasizing Statin Safety in the Hospitalized Patient: A Review. <i>American Journal of Medicine</i> , 2012, 125, 845-853.	1.5	20
92	A Comparative Analysis of Current Lipid Treatment Guidelines. <i>Journal of the American College of Cardiology</i> , 2018, 71, 794-799.	2.8	20
93	Refining Statin Prescribing in Lower-Risk Individuals. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1690-1697.	2.8	19
94	Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. <i>American Heart Journal</i> , 2019, 209, 79-87.	2.7	19
95	Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies. <i>Journal of Clinical Lipidology</i> , 2021, 15, 22-32.e12.	1.5	19
96	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 1. <i>American Journal of Medicine</i> , 2019, 132, e569-e580.	1.5	18
97	Management of severe hypertriglyceridemia in the hospital: A review. <i>Journal of Hospital Medicine</i> , 2012, 7, 431-438.	1.4	17
98	Lowering LDL Cholesterol Is Good, but How and in Whom?. <i>New England Journal of Medicine</i> , 2015, 372, 1564-1565.	27.0	17
99	COCATS 4 Task Force 2: Training in Preventive Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1754-1762.	2.8	17
100	Reducing Residual Risk in Secondary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2012, 125, 1958-1960.	1.6	16
101	Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. <i>American Journal of Cardiology</i> , 2015, 116, 481-484.	1.6	16
102	The ABCDs of Lifestyle Counseling. <i>JAMA Cardiology</i> , 2016, 1, 505.	6.1	16
103	Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. <i>American Journal of Medicine</i> , 2019, 132, e693-e700.	1.5	16
104	A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy. <i>American Journal of Medicine</i> , 2020, 133, 1322-1327.	1.5	16
105	Comparing Primary Prevention Recommendations. <i>Circulation</i> , 2020, 141, 1117-1120.	1.6	16
106	Optimizing the Potential for Telehealth in Cardiovascular Care (in the Era of COVID-19): Time Will Tell. <i>American Journal of Medicine</i> , 2021, 134, 945-951.	1.5	16
107	Successful control of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes. <i>Clinical Cornerstone</i> , 2006, 8, S15-S20.	0.7	15
108	Severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2012, 6, 397-408.	1.5	15

#	ARTICLE	IF	CITATIONS
109	Nondietary Cardiovascular Health Metrics With Patient Experience and Loss of Productivity Among US Adults Without Cardiovascular Disease: The Medical Expenditure Panel Survey 2006 to 2015. <i>Journal of the American Heart Association</i> , 2020, 9, e016744.	3.7	15
110	Stopping Statins. <i>Circulation</i> , 2004, 110, 2280-2282.	1.6	14
111	Statins and Nonadherence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 447-456.	2.0	14
112	The Role of Sex-Specific Risk Factors in the Risk Assessment of Atherosclerotic Cardiovascular Disease for Primary Prevention in Women. <i>Current Atherosclerosis Reports</i> , 2020, 22, 46.	4.8	14
113	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. <i>Journal of the American Heart Association</i> , 2020, 9, e017915.	3.7	14
114	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	14
115	Electrophysiological Studies on Uremic Patients - Comparison of Peritoneal Dialysis and Hemodialysis. <i>Clinical EEG (electroencephalography)</i> , 1980, 11, 72-82.	0.9	12
116	Statin therapy across the lifespan: evidence in major age groups. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 341-366.	1.5	12
117	Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. <i>Circulation</i> , 2019, 139, 410-412.	1.6	12
118	Hemodialysis vs. peritoneal dialysis: Results of a 3-year prospective controlled study. <i>Kidney International</i> , 1981, 19, 341-348.	5.2	11
119	Secondary prevention and lipid lowering: Results and implications. <i>American Heart Journal</i> , 1985, 110, 1123-1127.	2.7	10
120	Metabolic syndrome management. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2059-2075.	1.8	10
121	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. <i>American Journal of Medicine</i> , 2019, 132, e599-e609.	1.5	10
122	Cholesterol, colestipol and coronary heart disease. <i>Journal of Chronic Diseases</i> , 1978, 31, 1-3.	1.2	9
123	Midterm Benefits of Preoperative Statin Therapy in Patients Undergoing Isolated Valve Surgery. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1881-1887.	1.3	9
124	A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 2010-2013.	0.9	9
125	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 2-6.	3.1	9
126	Diet, blood cholesterol levels, and coronary heart disease. <i>Coronary Artery Disease</i> , 1993, 4, 871-882.	0.7	8

#	ARTICLE	IF	CITATIONS
127	Lowering low-density cholesterol with diet: the important role of functional foods as adjuncts. <i>Coronary Artery Disease</i> , 2001, 12, 547-552.	0.7	8
128	Long-term survival of childhood coronary artery disease in a patient severely affected with familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2004, 94, 699-700.	1.6	8
129	Evidence-based treatment of lipids in the elderly. <i>Current Atherosclerosis Reports</i> , 2004, 6, 388-397.	4.8	8
130	Nonpharmacologic Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and the Metabolic Syndrome: A Review of the Evidence. <i>American Journal of Cardiology</i> , 2008, 102, 14L-18L.	1.6	8
131	Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines. <i>Journal of Clinical Lipidology</i> , 2019, 13, 356-359.	1.5	8
132	Guidelines for Cardiovascular Risk Assessment and Cholesterol Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2235.	7.4	7
133	Statins in Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2707-2709.	2.8	7
134	Update on the omega-3 fatty acid trial landscape: A narrative review with implications for primary prevention. <i>Journal of Clinical Lipidology</i> , 2021, 15, 545-555.	1.5	7
135	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2660-2670.	3.0	7
136	Primary Prevention Statins in Older Adults: Personalized Care for a Heterogeneous Population. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 467-473.	2.6	6
137	Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease—Perspective from the Veterans Affairs Healthcare System. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	2.6	6
138	Eruptive Xanthomas: Importance of Recognition to Reduce Delay of Effective Triglyceride Reduction. <i>American Journal of Medicine</i> , 2022, 135, 444-447.	1.5	6
139	Shared decision making and patient reported outcomes among adults with atherosclerotic cardiovascular disease, medical expenditure panel survey 2006–2015. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100281.	3.0	6
140	Controlling cholesterol levels through diet. <i>Postgraduate Medicine</i> , 1988, 83, 229-242.	2.0	5
141	Goals of statin therapy: Three viewpoints. <i>Current Atherosclerosis Reports</i> , 2002, 4, 26-33.	4.8	5
142	Advances in Lipid Testing: A Practical Step Forward. <i>Clinical Chemistry</i> , 2016, 62, 905-906.	3.2	5
143	Preventing Atherosclerotic Cardiovascular Disease Using American College of Cardiology and American Heart Association Prevention Guidelines: Some Good News, But Caveats Remain. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	5
144	Factors Affecting the Cost of Airplanes and Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 596.	6.1	5

#	ARTICLE	IF	CITATIONS
145	Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2019, 123, 368-374.	1.6	5
146	Effects of dietary modification to reduce vascular risks and treatment of obesity. <i>Cardiology Clinics</i> , 2003, 21, 415-433.	2.2	4
147	Goals of Statin Therapy: Three Viewpoints. <i>Atherosclerosis Supplements</i> , 2004, 5, 107-114.	1.2	4
148	Lipids and Women's Health: Recent Updates and Implications for Practice. <i>Journal of Women's Health</i> , 2019, 28, 752-760.	3.3	4
149	Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2016, 164, 135.	3.9	4
150	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. <i>Journal of Clinical Lipidology</i> , 2021, 15, 832-839.	1.5	4
151	Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia. <i>Clinical Cardiology</i> , 2021, 44, 186-192.	1.8	4
152	Treating Severe Hypercholesterolemia—If Not Now, When?. <i>JAMA Cardiology</i> , 2022, 7, 128.	6.1	4
153	The hyperlipidemias and coronary artery disease. <i>Disease-a-Month</i> , 1972, 18, 1-35.	1.1	3
154	The optimal dietary strategy to manage risk associated with various dyslipidemias. <i>Current Cardiology Reports</i> , 2001, 3, 391-400.	2.9	3
155	Should the Routine Physical Examination Include Squat Maneuvers?. <i>American Journal of Medicine</i> , 2011, 124, 702-704.	1.5	3
156	Reply. <i>Journal of Vascular Surgery</i> , 2014, 59, 876.	1.1	3
157	Primary Risk Prevention in the Elderly: Use Clinician-Patient Discussions, Not Automatic Statin Prescribing. <i>American Journal of Medicine</i> , 2015, 128, 804-806.	1.5	3
158	The Pooled Cohort Equations for Predicting Risk of Myocardial Infarction and Stroke: Validated in Representative Natural History Populations. <i>Mayo Clinic Proceedings</i> , 2016, 91, 692-694.	3.0	3
159	New Eyes on Lipids and Lipoproteins. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 95-96.	3.1	3
160	Tracking Residual Risk. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1451-1453.	2.8	3
161	Coronary Artery Calcium: Where Do We Stand After Over 3 Decades?. <i>American Journal of Medicine</i> , 2021, 134, 1091-1095.	1.5	3
162	Commentary. <i>Clinica Chimica Acta</i> , 2003, 332, 21.	1.1	2

#	ARTICLE	IF	CITATIONS
163	Application of Recent Definitions of the Metabolic Syndrome to Survey Data From the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 295-300.	1.7	2
164	The 75-Year-Old Patient with Hypercholesterolemia: To Treat or Not to Treat?. <i>Nutrition Reviews</i> , 2009, 52, 31-33.	5.8	2
165	Healthy Lifestyle Behaviors and Triglycerides. <i>Lippincott S Bone and Joint Newsletter</i> , 2011, 37, 1-5.	0.0	2
166	Letter by Stone et al Regarding Article, "Perspective on the 2013 American Heart Association/American College of Cardiology Guideline for the Use of Statins in Primary Prevention of Low-Risk Individuals". <i>Circulation Research</i> , 2014, 115, e1-2.	4.5	2
167	Getting Guidelines Correct. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2051-2052.	2.8	2
168	Potential for Net Benefit Should Guide Preventive Therapy. <i>Circulation</i> , 2017, 135, 630-632.	1.6	2
169	Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100117.	3.0	2
170	Hyperlipidemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 1998, 9, 279-281.	2.7	2
171	Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. <i>Journal of Clinical Lipidology</i> , 2021, , .	1.5	2
172	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. <i>PLoS ONE</i> , 2020, 15, e0240166.	2.5	2
173	Hyperlipidaemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2001, 12, 667-669.	2.7	1
174	Are Statins Indicated for the Primary Prevention of Coronary Heart Disease in Octogenarians? Protagonist Viewpoint. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 351-354.	0.6	1
175	Hyperlipidaemia and cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2004, 15, 707-709.	2.7	1
176	The Metabolic Syndrome in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2005, 25, 233-234.	0.5	1
177	Clinical Confidence and the Three C's: Caring, Communicating, and Competence. <i>American Journal of Medicine</i> , 2006, 119, 1-2.	1.5	1
178	Effect of Amiodarone-Induced Hyperthyroidism on Left Ventricular Outflow Obstruction After Septal Myectomy for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2010, 106, 1670-1672.	1.6	1
179	Cholesterol Guidelines Do Not Endorse "One Size Fits All". <i>Journal of the American College of Cardiology</i> , 2015, 65, 1640-1643.	2.8	1
180	Looking Beyond Statins. <i>Circulation</i> , 2016, 134, 1944-1947.	1.6	1

#	ARTICLE	IF	CITATIONS
181	MY APPROACH to cardiovascular risk assessment to reduce atherosclerotic risk. Trends in Cardiovascular Medicine, 2016, 26, 92-93.	4.9	1
182	Sudden Creatine Kinase Elevation When an Athlete Starts Boxing: Looking Deeper Prior to Knocking the Statin Out. American Journal of Medicine, 2018, 131, e333-e334.	1.5	1
183	A New HOPE? Lessons from Heart Outcomes Prevention Evaluation-3. American Journal of Medicine, 2018, 131, 134-140.	1.5	1
184	Treating Hypercholesterolemia in Older Adults. JAMA - Journal of the American Medical Association, 2019, 322, 695.	7.4	1
185	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiology, 2019, 4, 473.	6.1	1
186	Worth Remembering: Cardiac Memory Presenting as Deep Anterior T-Wave Inversions Explained by Intermittent Left Bundle Branch Block. American Journal of Cardiology, 2020, 135, 174-176.	1.6	1
187	Necessity of Coronary CT Scans. JAMA Internal Medicine, 2021, 181, 1258.	5.1	1
188	Strategies for Treating Abnormal Lipid Profiles with Drugs. , 2011, , 163-193.		1
189	Current drug treatments for lipid management. Managed Care, 2002, 11, 4-9.	0.3	1
190	Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology, 1999, 10, 479.	2.7	0
191	Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology, 2000, 11, 437-439.	2.7	0
192	Approach to the Patient with Hyperlipidemia. , 2001, , 115-132.		0
193	Therapy and clinical trials. Current Opinion in Lipidology, 2004, 15, 97-99.	2.7	0
194	Therapy and clinical trials. Current Opinion in Lipidology, 2006, 17, 199-201.	2.7	0
195	Practical management of patients with hypertension and metabolic risk factors: Using lifestyle to reduce risk. Current Cardiovascular Risk Reports, 2008, 2, 262-267.	2.0	0
196	Look Before You Leap (Treat): Severely Low High-density Lipoprotein Cholesterol. American Journal of Medicine, 2013, 126, e1-e2.	1.5	0
197	Drugs for Elevated Low-Density Lipoprotein Cholesterol. , 2013, , 421-433.		0
198	Understanding the new atherosclerotic cardiovascular disease prevention guidelines: going beyond the headlines. Clinical Lipidology, 2014, 9, 121-123.	0.4	0

#	ARTICLE	IF	CITATIONS
199	Metabolic Profilesâ€”Based on the 2013 Prevention Guidelines. , 2016, , 83-88.		0
200	Reply. Journal of the American College of Cardiology, 2016, 68, 1710-1711.	2.8	0
201	Author's Reply. Clinical Cardiology, 2016, 39, 307-307.	1.8	0
202	New Strategies to Treat High Cholesterol. JAMA - Journal of the American Medical Association, 2016, 315, 1169.	7.4	0
203	Getting What the Guidelines Stated Matters. Journal of the American College of Cardiology, 2016, 67, 119-120.	2.8	0
204	Use of Statins in Adults Older Than 75 Years. JAMA - Journal of the American Medical Association, 2017, 317, 1081.	7.4	0
205	Measuring Low-Density Lipoprotein Cholesterol. JAMA Cardiology, 2018, 3, 754.	6.1	0
206	Advanced Lipid Thinking Prior to Incorporating Advanced Lipid Testing. American Journal of Medicine, 2019, 132, 1279-1284.	1.5	0
207	JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product. Journal of Clinical Lipidology, 2019, 13, 345-355.	1.5	0
208	Editorial commentary: Risk factors, enhancing factors and ASCVD in inflammatory bowel diseases. Trends in Cardiovascular Medicine, 2020, 30, 470-471.	4.9	0
209	Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management. American Journal of Cardiology, 2020, 133, 1-6.	1.6	0
210	Cost-effectiveness of Statin Use Guidelines. JAMA Cardiology, 2021, 6, 363.	6.1	0
211	A â€”Rule of Thumbâ€” Aids Evaluation of Severe Hypercholesterolemia to Recognize Familial Hypercholesterolemia. American Journal of Medicine, 2021, 134, e510-e511.	1.5	0
212	Obesity and Lifestyle Modification. Fundamental and Clinical Cardiology, 2006, , 63-78.	0.0	0
213	Management of Lipids in the Elderly. , 2007, , 369-387.		0
214	Drugs for Elevated LDL-Cholesterol. , 2007, , 528-539.		0
215	Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia. , 2009, , 144-157.		0
216	Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease. , 2009, , 217-231.		0

#	ARTICLE	IF	CITATIONS
217	The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: A Personalized Approach to Risk Reduction. Contemporary Cardiology, 2021, , 179-200.	0.1	0
218	Comparison of 2018 AHA-ACC Multi-Society Cholesterol Guidelines with 2013 ACC-AHA Cholesterol Guidelines. Contemporary Cardiology, 2021, , 107-120.	0.1	0
219	Title is missing!., 2020, 15, e0240166.		0
220	Title is missing!., 2020, 15, e0240166.		0
221	Title is missing!., 2020, 15, e0240166.		0
222	Title is missing!., 2020, 15, e0240166.		0